Ophthalmology: This Is Enterprise Imaging

Ophthalmology

Enterprise Imaging has a new vision for eye care: Utilizing a single platform to streamline image viewing, analysis and storage and linking ophthalmology with other ‘ologies across the healthcare system. That vision is now a clinically proven reality as one platform unites eye care with other imaging exams across a large, U.S.-based healthcare system. Ophthalmologists and optometrists praise the solution for proving its value in eye disease diagnostics, care planning and patient outcomes—and now other healthcare systems can take advantage of it too.

Flurpiridaz data shows promise to expand and enhance cardiac PET

Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET. #ASNC
Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET.

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.